Jade Biosciences, Inc. - 8-K Filing

Jade Biosciences announced preclinical data for JADE301, its anti-IFN-beta monoclonal antibody in development for dermatomyositis. (Items: 8.01 Other Events)

SEC EDGAR ·

Tickers: $AVTE

Read the full article at SEC EDGAR

More Regulatory news